Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
Ernexa Therapeutics Inc. (ERNA)
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program (JEAP), a highly competitive initiative launched by the Japan External Trade Organization (JETRO). JEAP drew approximately 70 regenerative medicine companies from 25 countries, underscoring the competitiveness of the selection process. Ernexa was chosen for its differentiated cell therapy platform and its potential to contribute meaningfully to Japan’s globally recognized regenerative medicine and oncology ecosystem. Notably, six of the ten selected companies focus on oncology, placing Ernexa among an elite group recognized for innovation in one of the world’s most critical and high-value therapeutic areas. “Japan is a world leader in regenerative medic
Show less
Read more
Impact Snapshot
Event Time:
ERNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERNA alerts
High impacting Ernexa Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ERNA
News
- Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDAGlobeNewswire
- Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian CancerGlobeNewswire
- Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian CancerGlobeNewswire
- Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewswire
- Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOGGlobeNewswire
ERNA
Sec Filings
- 2/3/26 - Form S-1
- 12/19/25 - Form SCHEDULE
- 12/16/25 - Form SCHEDULE
- ERNA's page on the SEC website